X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN LTD ORCHID PHARMA LTD/
LUPIN LTD
 
P/E (TTM) x -0.7 16.6 - View Chart
P/BV x 0.5 3.9 13.9% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   LUPIN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN LTD
Mar-16
ORCHID PHARMA LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1942,127 9.1%   
Low Rs351,294 2.7%   
Sales per share (Unadj.) Rs276.5304.1 90.9%  
Earnings per share (Unadj.) Rs-79.250.4 -157.2%  
Cash flow per share (Unadj.) Rs-43.560.7 -71.6%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9243.8 22.1%  
Shares outstanding (eoy) m70.45450.58 15.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.6 7.4%   
Avg P/E ratio x-1.433.9 -4.3%  
P/CF ratio (eoy) x-2.628.2 -9.3%  
Price / Book Value ratio x2.17.0 30.3%  
Dividend payout %014.9 0.0%   
Avg Mkt Cap Rs m8,067770,740 1.0%   
No. of employees `0002.816.4 17.1%   
Total wages/salary Rs m2,52721,077 12.0%   
Avg. sales/employee Rs Th6,956.18,379.6 83.0%   
Avg. wages/employee Rs Th902.51,289.0 70.0%   
Avg. net profit/employee Rs Th-1,993.01,388.7 -143.5%   
INCOME DATA
Net Sales Rs m19,477137,016 14.2%  
Other income Rs m4071,877 21.7%   
Total revenues Rs m19,884138,893 14.3%   
Gross profit Rs m1,10337,535 2.9%  
Depreciation Rs m2,5194,635 54.4%   
Interest Rs m5,227446 1,171.4%   
Profit before tax Rs m-6,23634,330 -18.2%   
Minority Interest Rs m20-88 -22.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12511,536 -1.1%   
Profit after tax Rs m-5,58022,707 -24.6%  
Gross profit margin %5.727.4 20.7%  
Effective tax rate %2.033.6 6.0%   
Net profit margin %-28.716.6 -172.9%  
BALANCE SHEET DATA
Current assets Rs m11,01497,790 11.3%   
Current liabilities Rs m32,06053,872 59.5%   
Net working cap to sales %-108.132.1 -337.1%  
Current ratio x0.31.8 18.9%  
Inventory Days Days9585 112.0%  
Debtors Days Days34121 27.7%  
Net fixed assets Rs m29,44086,379 34.1%   
Share capital Rs m705901 78.2%   
"Free" reserves Rs m2,043105,735 1.9%   
Net worth Rs m3,800109,844 3.5%   
Long term debt Rs m9,01853,739 16.8%   
Total assets Rs m46,510224,378 20.7%  
Interest coverage x-0.277.9 -0.2%   
Debt to equity ratio x2.40.5 485.1%  
Sales to assets ratio x0.40.6 68.6%   
Return on assets %-0.810.3 -7.4%  
Return on equity %-146.920.7 -710.4%  
Return on capital %-3.721.2 -17.6%  
Exports to sales %37.949.1 77.2%   
Imports to sales %22.67.4 303.9%   
Exports (fob) Rs m7,37867,244 11.0%   
Imports (cif) Rs m4,40610,199 43.2%   
Fx inflow Rs m7,51371,405 10.5%   
Fx outflow Rs m5,64917,807 31.7%   
Net fx Rs m1,86553,598 3.5%   
CASH FLOW
From Operations Rs m1,682-3,690 -45.6%  
From Investments Rs m-9,860-69,434 14.2%  
From Financial Activity Rs m6,64458,126 11.4%  
Net Cashflow Rs m-1,535-14,998 10.2%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   WYETH LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - PANACEA BIOTECH COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS